"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK ...

Rituximab usage is expanding into the fields of autoimmune disease, and hence the number of patients receiving rituximab is increasing largely. Consistent with this trend, late adverse events of ...